The jury found the following in a patent infringement case between Idenix Pharmaceuticals LLC, Universita Degli Studi Di Cagliari and Gilead Sciences, Inc: 1) Gilead's infringement of the '597 Patent was willful. 2) Gilead did not prove by clear and convincing evidence that the '597 patent is invalid due to lack of enablement or written description. 3) Gilead did not prove by clear and convincing evidence that claims 1, 28, 30, 31 of the '597 patent are invalid due to anticipation. 4) Gilead did not prove by clear and convincing evidence that claims 1-2, 4-7,

1. IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
IDENIX PHARMACEUTICALS LLC
UNIVERSITA DEGLI STUDI DI
CAGLIARI,
Plaintiffs,
v.
GILEAD SCIENCES, INC.
Defendant.
C.A. No. 14-846-LPS
VERDICT FORM
Case 1:14-cv-00846-LPS Document 518 Filed 12/15/16 Page 1 of 4 PageID #: 32917

2. Ve, the jury, unanimously find as follows:
I. WILLFUL INFRINGEMENT
1. Have Idenix and the University proven by a preponderance ofthe evidence that
Gilead's infringement of the asserted claims ofthe '597 Patent was willful?
"Yes" is afinding for ldenix and the University. "No" is afinding for Gilead.
Yes/ No ___
II. INVALIDITY
A. ENABLEMENT
2. Has Gilead proven by clear and convincing evidence that each ofthe asserted claims
of the '597 patent is invalid because the specification of the '597 patent does not enable
the asserted claims?
"Yes" is afinding for Gilead. "No" is afinding for ldenix and the University.
Yes No/- - -
B. WRITTEN DESCRIPTION
3. Has Gilead proven by clear and convincing evidence that each of the asserted claims
of the '597 patent is invalid because the specification of the '597 patent does not contain
an adequate written description ofthe asserted claims?
"Yes" is afinding for Gilead. "No" is afinding for ldenix and the University.
Yes No/
C. ANTICIPATION
4. Has Gilead proven by clear and convincing evidence that any ofthe following claims
ofthe '597 patent is invalid for anticipation based on prior invention?
"Yes" is afindingfor Gilead. "No" is afinding for ldenix and the University.
Claim 1 Yes No /
Claim 28 Yes No v
Claim 30 Yes No v
Claim 31 Yes No v
Case 1:14-cv-00846-LPS Document 518 Filed 12/15/16 Page 2 of 4 PageID #: 32918

3. D. OBVIOUSNESS
5. Has Gilead proven by clear and convincing evidence that any ofthe following claims
of the '597 patent is invalid because the claimed subject matter would havelbeen obvious
to a person of ordinary skill in the art at the time of the claimed invention?
"Yes" is afinding for Gilead. "No" is afinding for Idenix and the University.
Claim 1 Yes No /
Claim 2 Yes No v
Claim 4 Yes No /
Claim 5 Yes No /
Claim 6 Yes No ~
Claim 7 Yes No v-
Claim 9 Yes No /
Claim 10 Yes No v
Claim 16 Yes No-/
Claim 19 Yes NoL
Claim 23 Yes No v
Claim 28 Yes No v
Claim 29 .Yes No v
Claim 30 Yes No v
Claim 31 Yes No ~
2
Case 1:14-cv-00846-LPS Document 518 Filed 12/15/16 Page 3 of 4 PageID #: 32919

4. III. DAMAGES (IF APPLICABLE)
Ifyou find that any ofthe asserted claims are valid, then you should answer this question.
Ifyou.find that all the asserted claims are invalid, then you should not answer this
question.
6. What is the reasonable royalty that Idenix and the University have proven by a
preponderance of the evidence that they are entitled to? (Fill out only (a) or (b).)
a. If you are awarding damages based on a running royalty, answer these
questions:
Royalty Rate: }0 %
Royalty Base: $ 2 5.-:j 6 i llDN
(total dollar value of U.S. sales of Sovaldi® and adjusted sales of
Harvoni® through August 2016)?
Total Amount through August 2016: $ 2. 5L/ ~LUo.r--J
(Royalty Rate percentage multiple by Royalty Base)
b. If you are awarding damages based on a lump sum, what is the lump sum
payment Idenix and the University are entitled to:.
You have now reached the end of the verdict form and you should review it to ensure it
accurately reflects your unanimous determinations. You must each sign the verdict form in the
spaces below and notify the Jury Officer that you have reached a verdict.
Dated: December IS-, 2016 ~- -- - --
3
Case 1:14-cv-00846-LPS Document 518 Filed 12/15/16 Page 4 of 4 PageID #: 32920